title: Posterior reversible encephalopathy syndrome induced by pazopanib for renal cell carcinoma.
abstract: OBJECTIVE
  Posterior reversible encephalopathy syndrome (PRES) can be the result of acute hypertension, eclampsia, renal failure and the use of immunosuppressive or cytotoxic agents. We report a case of PRES as a result of the use of pazopanib, a vascular endothelial growth factor inhibitor used for renal cell carcinoma (RCC).
  
  
  METHODS
  A 76-year-old man treated with RCC develops PRES shortly after the initiation of pazopanib.
  
  
  CONCLUSIONS
  There are no known reports of the association between PRES and pazopanib. We postulate that pazopanib can disrupt the normal endothelial function of the brain leading to the development of PRES.
authors.affiliation: Department of Neurology, University of Minnesota, Minneapolis, MN 55455, USA. ganesh785@gmail.com
authors.forename: G
authors.initials: G
authors.lastname: Asaithambi
authors.forename: B R
authors.initials: BR
authors.lastname: Peters
authors.forename: E
authors.initials: E
authors.lastname: Hurliman
authors.forename: B P
authors.initials: BP
authors.lastname: Moran
authors.forename: A S
authors.initials: AS
authors.lastname: Khan
authors.forename: R A
authors.initials: RA
authors.lastname: Taylor
mesh_terms: D000368:Aged; D002292:Carcinoma, Renal Cell / Q000188:drug therapy*; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D007191:Indazoles; D007680:Kidney Neoplasms / Q000188:drug therapy*; D008297:Male; D054038:Posterior Leukoencephalopathy Syndrome / Q000139:chemically induced*; D011743:Pyrimidines / Q000009:adverse effects* / Q000627:therapeutic use*; D013449:Sulfonamides / Q000009:adverse effects* / Q000627:therapeutic use*; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
chemical_list: D007166:Immunosuppressive Agents; D007191:Indazoles; D011743:Pyrimidines; D013449:Sulfonamides; D042461:Vascular Endothelial Growth Factor A; C516667:pazopanib